Мне крайне неприятно, что методики, позиционируемые,как биорезонанс, порочат саму суть данного явления. Биорезонанс,на самом деле, принят давно и успешно практикуется в мире ( метод Р.Райфа, Р.Фолля, Р.Шиммеля и т. д.) Во Франции данная методика входит в состав официальной медицины, как в обязательное, так и добровольное страхование. В Германии,только добровольное. У нас минздрав утвердил методики,но пока без "фанатизма" внедрения. Сегодня существует достаточное количество производителей различного оборудования, но по сути вегетативного резонанса, их не много. Данная наука только начинает развиваться в нашей стране и пока не имеет твердой научной базы, наработанной широким клиническим опытом.Основным направлением является антипаразитарная терапия, как основа рассмотрения любого приобретенного заболевания. Данная методика,пока единственная, способна оказывать прямое воздействие, к примеру, на вирусы. Развитию метода мешают системы МЛМ, внедряющиеся в любое,мало мальски значимое, начинание.
Мне крайне неприятно, что человек, позиционирующий себя как врач, порочит саму суть научной медицины. Это слово ни в одной интерпретации в приличном обществе произносить нельзя.
В том числе в шарлатанском контексте "антипаразитарной терапии, как основы"
Доктор, прежде чем Вы продолжите
1. Воздержитесь пожалуйста от постинга в консультативных темах
2. Возьмите за правило каждое свое высказывание подтверждать ссылкой на релевантный источник.
Боже мой, как я благодарна Вам, Егор Николаевич, от всех врачей! Биорезонансная терапия хорошо спланированный и прибыльный бизнес. Но попробуй об этом честно и громко сказать!
Это по-видимому не следует называть "биорезонансом", но новую тему создавать не хотелось бы, а более подходящей не нашел:
[Ссылки доступны только зарегистрированным пользователям ]
Цитата:
Laboratory and clinical evidence suggests that certain frequencies within the RF EMF range of the spectrum may have antitumor effects without causing hyperthermia in patients with breast cancer, HCC, ovarian cancer, thyroid cancer, or glioblastoma multiforme [20]–[22].
[Ссылки доступны только зарегистрированным пользователям ]
Цитата:
The NovoTTF-100A technology applies alternating electric fields by means of electrodes placed on the skin overlying tumor-harboring body parts. This was the first EMF device of its kind approved by the Food and Drug Administration (FDA) of the United States based on the results of a phase III trial for treating recurrent glioblastoma showing efficacy similar to the standard-of-care chemotherapy regimen but with fewer adverse effects[23]
[Ссылки доступны только зарегистрированным пользователям ]
Цитата:
Аbstract
Background:
There is clinical evidence that very low and safe levels of amplitude-modulated electromagnetic fields administered via an intrabuccal spoon-shaped probe may elicit therapeutic responses in patients with cancer. However, there is no known mechanism explaining the anti-proliferative effect of very low intensity electromagnetic fields.
Methods:
To understand the mechanism of this novel approach, hepatocellular carcinoma (HCC) cells were exposed to 27.12 MHz radiofrequency electromagnetic fields using in vitro exposure systems designed to replicate in vivo conditions. Cancer cells were exposed to tumour-specific modulation frequencies, previously identified by biofeedback methods in patients with a diagnosis of cancer. Control modulation frequencies consisted of randomly chosen modulation frequencies within the same 100 Hz–21 kHz range as cancer-specific frequencies.
Results:
The growth of HCC and breast cancer cells was significantly decreased by HCC-specific and breast cancer-specific modulation frequencies, respectively. However, the same frequencies did not affect proliferation of nonmalignant hepatocytes or breast epithelial cells. Inhibition of HCC cell proliferation was associated with downregulation of XCL2 and PLP2. Furthermore, HCC-specific modulation frequencies disrupted the mitotic spindle.
Conclusion:
These findings uncover a novel mechanism controlling the growth of cancer cells at specific modulation frequencies without affecting normal tissues, which may have broad implications in oncology.
Значит будем надеяться на скорейшее открытие и официальное утверждение аппаратов, способных менять ДНК. Я никогда не сомневалась в том, что наука не стоит на месте и настанет день, когда человек сможет повлиять и на генетику...
Цитата:
Сообщение от LupusDoc;
Вы, видимо, говорите об аппаратах, которые смогут изменить ДНК в живом человеке (если, конечно, не шутите...).
Этого точно не произойдет ни при нашей жизни, ни при жизни наших детей. И сильно сомневаюсь, что вообще когда-либо будет создан такой аппарат...
[Ссылки доступны только зарегистрированным пользователям ]
Цитата:
For the first time, researchers have infused a person’s blood with gene-editing tools, aiming to treat his severe inherited disease.
This week, a UCSF Benioff Children’s Hospital Oakland’s adult patient underwent a landmark gene editing therapy – marking the first time that genome editing has been done inside a human body in an effort to change the DNA of a patient with a rare genetic disease.
The gene editing treatment is part of a clinical trial between UCSF Benioff Children’s Hospital Oakland and Sangamo Therapeutics – an “in vivo” genome editing therapy for people with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
The trial, being lead in at the hospital by UCSF Benioff Oakland’s Paul Harmatz, M.D. whose patient, Brian Madeux, had previously participated in other clinical trials for MPS II and who is a long-term patient of Dr. Harmatz.
“We are proud to be part of this groundbreaking trial and it is our hope that the gene editing therapy will produce benefits to our patient and other MPS patients that will greatly contribute to an improved quality of life. We are grateful to our patient Brian for being the first person to participate in the trial,” said Dr. Harmatz, M.D., a pediatric gastroenterologist and a principal investigator for the study at the UCSF Benioff Children's Hospital Oakland.
The clinical trial aims to treat MPS II by using genome editing to insert a corrective gene into a precise location in the DNA of liver cells with the goal of enabling a patient's liver to produce a lifelong and stable supply of an enzyme he or she currently lacks.
Without that enzyme, people with MPS II suffer a debilitating buildup of toxic carbohydrates in cells throughout their body. Approximately one in 100,000 to one in 170,000 people are born with MPS II. Many people with MPS II receive weekly infusions of enzyme replacement therapy (ERT), the current standard-of-care treatment. Within a day of receiving ERT, however, IDS quickly returns to near undetectable levels in the blood.
"Even with regular infusions of ERT, which has markedly improved functional health outcomes, patients endure progressive damage to heart, bones, and lungs. Many patients with MPS II die of airway obstruction, upper respiratory infection or heart failure before they reach the age of 20," said Dr. Harmatz.
"Living with Hunter's Syndrome is not a pain-free life. I have pain every second of the day,” said Madeux. “I have learned to manage my issues as they arise, through the help of doctors and by staying active. There are people dealing with far worse. I go day by day. I actually thought I wouldn't live past my early 20's, but the way I lived my life has surely helped me to live longer. Being an athlete growing up and working in the hospitality industry has helped."
He decided to participate in the groundbreaking study because he wanted to give something back to others living with inherited conditions like him, "I am willing to take the minimal risk of changing my own DNA if it will prolong my life and help scientists find cures for humankind".
The therapy is part of Phase 1/2 clinical trial ("the CHAMPIONS study") evaluating SB-913, an investigational in vivo genome editing therapy. SB-913 makes use of Sangamo's zinc finger nuclease (ZFN) genome editing technology to insert a corrective gene into a precise location in the DNA of liver cells. To restrict editing to liver cells, the ZFNs and the corrective gene are delivered in a single intravenous infusion using AAV vectors that target the liver. The ZFNs enter the cells as inactive DNA instructions in a format designed only for liver cells to unlock. Once "unlocked", the ZFNs then identify, bind to and cut the DNA in a specific location within the albumin gene. Using the cells' natural DNA repair processes, liver cells can then insert the corrective gene for IDS at that precise location.
"For the first time, a patient has received a therapy intended to precisely edit the DNA of cells directly inside the body. We are at the start of a new frontier of genomic medicine," said Dr. Sandy Macrae, CEO of Sangamo Therapeutics.
The CHAMPIONS study is an open-label clinical study designed to assess the safety, tolerability and preliminary efficacy of the SB-913 investigational genome editing therapy in up to nine adult males with MPS II.
UCSF Benioff Children’s Hospital Oakland’s gastroenterology research group, under the direction of Dr. Paul Harmatz, is focused on translational and clinical research on the treatment of lysosomal storage diseases focused primarily on the mucopolysaccharidoses.
The mucopolysaccharidoses (MPS) are a group of 11 rare genetic disorders in the lysosomal storage disease (LSD) family, each caused by the absence or reduced function of lysosomal enzymes needed to break down glycosaminoglycans (GAGs). GAGs are long chains of carbohydrate constituents of bone, cartilage, and connective tissue. In the absence of lysosomal enzyme function, these GAGs collect in the cells and connective tissues and result in progressive cellular damage and organ system dysfunction. The mucopolysaccharidoses share many clinical features but have varying degrees of severity.
Treating these patients has depended on medical and surgical care, with hematopoietic stem cell transplantation as the only cure.
Since 2003, enzyme replacement therapy (ERT) has been approved for MPS I , II and VI provide specific therapy administered intravenously. Dr. Harmatz participated in the clinical trials for MPS II and VI that led to FDA approval. Dr. Harmatz lead one of only two US sites that participated in a longitudinal, multicenter, multinational natural history study for MPS IVA or Morquio A. He was also PI of one the US sites for the phase 3, randomized, placebo-controlled trial of enzyme replacement therapy that lead to the U.S. Food and Drug Administration (FDA) approval of a drug for patients with MPS IVA (Morquio A syndrome).
In addition to these trials, Dr. Harmatz and his colleagues have participated in the NIH-sponsored Lysosomal Disease Network studies and enrolled patients into a longitudinal study of brain disease in MPS I and II.
...Способы "влияния на генетику" совершенно другие и не связаны с "чудо-аппаратами"....
[Ссылки доступны только зарегистрированным пользователям ]
Цитата:
Several studies have reported EMF-mediated induction of cellular stress responses through the activation of heat shock proteins (HSPs)[35]. These findings support the theory that EMF activates a common pathway mediated by HSP70, and more specifically, that EMF may interact with specific DNA sequences in genes' promoter regions[36].
[Ссылки доступны только зарегистрированным пользователям ]
Цитата:
Modulation of gene expression was also reported in a tissue- and tumor-specific manner in cells exposed to RF EMF amplitude-modulated at specific frequencies[43].
[Ссылки доступны только зарегистрированным пользователям ]
Цитата:
Having identified a reproducible growth inhibitory effect of tumor-specific frequencies in several cancer cell lines, we used RNA-seq technology to comprehensively examine the gene expression profile of HepG2 cells exposed to HCC-specific vs. randomly selected modulation frequencies. We observed changes in expression in a small number of genes. Two of them, proteolipid protein 2 (PLP2) and chemokine (c motif) ligand 2 (XCL2), appeared to be down-regulated with an absolute fold change greater than 1.8 in HepG2 cells exposed to HCC-specific modulation frequencies. Using quantitative polymerase chain reaction (qPCR), we validated the down-regulation of these 2 genes not only in HepG2 cells but also in Huh7 cells.
[Ссылки доступны только зарегистрированным пользователям ]
Цитата:
...studies with model biochemical systems suggest that EMF could interact directly with electrons in DNA...
Здесь зачастую размещаются информационные сообщения соответствующие тематике раздела. Или я неправильно понимаю ситуацию ? Ничьи интересы я не лоббирую. Информация на мой взгляд интересная. У Вас есть какие-то замечания ?
Конечно есть. Вы заходите на форум врачебных консультаций и выкладываете набор ссылок на что-то.
Консультация подразумевает наличие вопроса, по которому консультируемый хочет получить информацию у специалиста.
У Вас есть какой-то вопрос? Или Вы считаете себя врачом - специалистом?
В противном случае Вы нарушаете правила.
Я Вас понял. Мне не составит труда больше не писать в разделе "Правда о целителях". Буду признателен если Вы удалите размещенные мною сообщения, поскольку в такой форме они, как Вы мне разъяснили, - не могут быть размещены лицом с таким статусом как мой
03.01.2012, 01:29
Линейный вид
